CD36 and metabolic dysfunction-associated steatotic liver disease: Previous studies indicated that hepatic CD36/fatty acid translocase expression were abnormally increased in non-alcoholic fatty liver disease (NAFLD), the forced expression of hepatic CD36 increased hepatic triglyceride storage and plasma triglyceride levels in mice fed a standard chow diet, and increased expression and function of CD36 in hepatocytes could contribute to steatosis not only in rodents but also in humans [36–38].